|
|
Il s’agissait d’une étude multicentrique, ouverte, de phase III au cours de laquelle les participants adultes dont la charge virale était supérieure ou égale à 400 copies/mL ont été randomisés afin de recevoir 1 200 mg d’amprénavir deux fois par jour ou 800 mg d’indinavir trois fois par jour, chacun administré en association avec deux INTI. Les volontaires devaient avoir reçu un traitement nucléosidique (AZT, ddI, ddC, 3TC ou d4T) pendant au moins 12 semaines et n’avoir jamais reçu d’inhibiteurs de la protéase.
|
|
|
This was a multicentre, open-label, phase III study where adult participants with a viral load above or equal to 400 copies/ml were randomized to receive amprenavir 1200 mg twice daily or indinavir 800 mg three times daily, each given in combination with two NRTIs. Volunteers had to have received nucleoside therapy (AZT, ddI, ddC, 3TC or d4T) for at least 12 weeks and have never received a protease inhibitor. They were encouraged to change their background NRTI therapy when they entered the study, and were eligible to change their randomized treatment if the switch criteria as specified in the protocol were met. Participants were stratified by screening viral load and whether or not a change in NRTI therapy was planned at the onset.
|
